Healthcare industry

Press release - 13/11/2012

immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment

immatics biotechnologies GmbH announced that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma RCC. The first interim overall survival results are expected during the first half of 2014.

Press release - 09/11/2012

Apogenix’s Apocept™ for glioblastoma multiforme named one of “Top 10 Projects to Watch”

Apogenix a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases announced that its lead product Apocept APG101 has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncologys Top 10 Projects To Watch.

Press release - 02/10/2012

Making cell division impossible: Optimized substance forces cancer cells into death

Many tumor cells have a defective cellular equipment. It is only by a special trick that they manage to distribute their chromosomes correctly to their daughter cells during cell division. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now developed a substance that thwarts this trick and forces cancer cells into death during cell division. The group has now reported their results in the journal…

Press release - 21/08/2012

Freiburg research team sheds light on important metabolite in bacteria

Scientists from the research groups of Prof. Dr. Susana Andrade and Prof. Dr. Oliver Einsle, members of the Institute of Organic Chemistry and BIOSS Centre for Biological Signalling Studies, Cluster of Excellence of the University of Freiburg, have collected the first precise data ever on the function of a transport protein for formate – an important metabolite in bacteria. The findings could potentially lead to the development of new antibiotic…

Press release - 08/08/2012

Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial

The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…

Press release - 25/10/2011

Research Initiative to Combat Cell Ageing

Insilico Biotechnology and its partners have started a joint large-scale research project to study how reactive oxygen species trigger ageing processes on the cell and tissue level and how to prevent these if possible. Biomarkers will be used to expose the processes and molecular target structures will be identified which can be targeted with active agents to delay ageing.

Article - 25/07/2011

Cell culturing as a taught subject: many more “Biberachs” are needed

Cell culture technology is only taught at a handful of universities. However, this interdisciplinary subject is the core of the “Pharmaceutical Biotechnology” programme offered by the Biberach University of Applied Sciences. We talked about the subject with Professor Jürgen Hannemann, founding dean of the “Pharmaceutical Biotechnology” programme, and with Professor Friedemann Hesse, who runs the “cell culture technology” teaching programme.

Article - 16/05/2011

New analysis tools involving molecularly imprinted polymers

The demand for made-to-measure analytical methods is increasing as interest in the biological production of materials and pharmaceuticals increases. It is extremely important economically for bioindustry to know the production time and quantity of products that result from specific fermentation conditions. Inspired by natural molecular processes, researchers from Tübingen and Stuttgart are working on new, label-free analytical methods that make…

Press release - 16/11/2010

Nycomed is keeping the pace in third quarter 2010 - US Food & Drug Administration to decide on the approval of Daxas®

Nycomed’s strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pantoprazole. Daxas® (roflumilast) has recently been launched in the first EU markets and further launches are underway over the coming months. To accelerate the expansion in China, one of the fastest…

In the first quarter of 2008 Nycomeds adjusted EBITDA increased by 6.2 to 304.0 million compared to 286.3 million in the first quarter of 2007 benefiting from the cost decreasing effects of last years restructuring.

Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India. Based on this agreement, Nycomed plans to transfer the current chemical production from the sites in Linz (Austria) and Singen (Germany) to the new joint venture within the next three to four…